Phase 3 RCT in 390 adults with high-risk nasopharyngeal carcinoma after induction chemotherapy: adding camrelizumab to chemoradiotherapy and as maintenance improved 36-month PFS (83.4% vs 71.3%; HR 0.51). Grade 3-4 acute adverse events 50.5% vs 48.7%.
RCTn = 390
You et al. Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial